# US 9,518,125 B2 · Composition for diagnosing liver cancer and methods of diagnosing liver cancer and obtaining information for diagnosing liver cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 9,518,125 B2
- Document ID: US9518125B2
- Status: Granted
- Kind: B2
- Application number: 14/322,570
- Filed: 2014-07-02
- Published: 2015-04-16
- Granted: 2016-12-13
- Earliest claimed: 2013-10-15
- Assignees: Samsung Electronics Co., Ltd.
- Applicants: Samsung Electronics Co., Ltd.
- Inventors: Ye-ryoung Yong; Hyun-ju Kang; Ga-hee Kim; Kyung-hee Park; Jong-myeon Park
- Web page: https://patentgrep.com/patent/US9518125B2

## CPC

- C07K 16/303: {Liver or Pancreas}
- C07K 16/2896: {against molecules with a "CD"-designation, not provided for elsewhere}
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Provided is method of diagnosing liver cancer in a subject, the method comprising contacting a sample from a subject with a substance that specifically binds to transmembrane emp24 domain trafficking protein 2 (TMED2), cluster of differentiation 43 (CD43), or any combination thereof on the surface of a microvesicle; and measuring the level of the substance bound to microvesicles in the sample; and related methods and compositions.

## Claims

### Claim 1

A method of diagnosing liver cancer in a subject, the method comprising:
contacting a sample from a subject with a substance that specifically binds to transmembrane emp24 domain trafficking protein 2 (TMED2) on the surface of a microvesicle in the sample to provide a mixture of the sample and the substance, wherein the substance is an anti-TMED2 antibody fixed to a solid support, thereby forming a complex between the anti-TMED2 antibody fixed to the solid support and the TMED2 on the surface of the microvesicle;
separating the complex from the mixture;
measuring the level of a marker for a microvesicle from the complex in the sample, wherein the marker is a surface protein on the microvesicle selected from the group consisting of CD63, CD83, integrin-beta 1 (ITGB1), CD9, CD36, CD81, EpCAM, caveolin, FasL, HLA-DRA, MUC1, ERBB4, GPER, ERBB2, MLANA, and AMHR2;
measuring the level of the marker for a microvesicle in a control sample; and
determining that the subject has a liver cancer when the level of the marker for a microvesicle in the sample is greater than that in the control sample,
wherein the control sample includes a plurality of samples obtained from cirrhosis patients.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the marker for a microvesicle is integrin-β1.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the solid support is a magnetic microparticle or a magnetic nanoparticle.

### Claim 4 (depends on 1)

The method according to claim 1, further comprising lysing the microvesicle in the complex after the separating step and before the measuring step to produce a lysate of the microvesicle.

### Claim 5 (depends on 4)

The method according to claim 4, wherein the measuring step comprises conducting an electrophoresis for the lysate and then western blotting.

### Claim 6 (depends on 5)

The method according to claim 5, wherein the anti-TMED2 antibody is attached to a detectable label.